Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11207384 | 0.86 | HDAC1 (0.57) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL22486922 | 0.83 | PLK1 (0.49) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL14454655 | 0.81 | HDAC6 (0.60) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL9969427 | 0.79 | KMT2A (0.57) | — | |
| SCHEMBL19521968 | 0.79 | THRB (0.41) | — | |
| SCHEMBL6396317 | 0.79 | ALDH1A1 (0.55) | — | |
| SCHEMBL6918978 | 0.79 | PLK1 (0.72) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL19002551 | 0.79 | CYP4A11 (0.62) | — | |
| SCHEMBL18701020 | 0.78 | MLYCD (0.42) | — | |
| SCHEMBL6919330 | 0.76 | PLK1 (0.74) | HDAC1HDAC6HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165257-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165257-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER | HDAC1, HDAC3, HDAC4 | HDAC1 1/4885HDAC6 10/4885HDAC8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.